Home Page

PUNE, India, July 28, 2016 /PRNewswire-iReach/ -- Prostate Cancer Market Research Companies Involved in Therapeutics Development are 4SC AG ,AB Science SA ,AbbVie Inc. ,Acino International AG ,Actinium Pharmaceuticals, Inc. ,Adamis Pharmaceuticals Corporation ,ADC Therapeutics Sarl ,Aduro BioTech, Inc. ,Advanced Accelerator Applications S.A. ,Advanced Cancer Therapeutics ,Advantagene, Inc. ,Advaxis, Inc. ,Aeglea BioTherapeutics, Inc. ,Aeolus Pharmaceuticals, Inc. ,Aeterna Zentaris Inc. ,Aileron Therapeutics, Inc. ,Akshaya Bio Inc. ,Alchemia Limited ,Alethia Biotherapeutics Inc. ,Almac Discovery Limited ,Ambrx, Inc. ,American Gene Technologies International Inc. ,Amgen Inc. ,Anavex Life Sciences Corp. ,AndroScience Corporation ,AnGes MG, Inc. ,AntiCancer, Inc. ,Antigen Express, Inc. ,Antisense Therapeutics Limited ,Apac Biotech Pvt Ltd ,Apcure SAS ,Aphios Corporation ,APIM Therapeutics AS ,Aptose Biosciences Inc. ,Armour Therapeutics Inc. ,Arno Therapeutics, Inc. ,ArQule, Inc. ,Arrien Pharmaceuticals, LLC ,Arrowhead Pharmaceuticals, Inc. ,Arvinas, Inc. ,Asana BioSciences, LLC ,Astellas Pharma Inc. ,Asterias Biotherapeutics, Inc. ,AstraZeneca Plc ,ATLAB Pharma SAS ,Avipep Pty Ltd ,Azaya Therapeutics, Inc. ,Bavarian Nordic A/S ,Baxalta Incorporated ,Bayer AG ,Bexion Pharmaceuticals, LLC. ,BHR Pharma, LLC ,BIND Therapeutics, Inc. ,Bio-Cancer Treatment International Limited ,Bionature E.A. Ltd. ,Biotest AG ,Biscayne Pharmaceuticals, Inc. ,Blirt S.A. ,Boehringer Ingelheim GmbH ,Bristol-Myers Squibb Company ,Camurus AB ,Can-Fite BioPharma Ltd. ,CEL-SCI Corporation ,Celgene Corporation ,CellCentric Ltd ,Cellceutix Corporation ,Celldex Therapeutics, Inc. ,Cellectar Biosciences, Inc. ,Celprogen, Inc. ,Chamaeleo Pharma NV ,CohBar, Inc. ,Colby Pharmaceutical Company ,Corcept Therapeutics Incorporated ,Corvus Pharmaceuticals, Inc. ,Crescendo Biologics Limited ,CureVac GmbH ,CytoVac A/S ,CZ BioMed Corp ,Deciphera Pharmaceuticals, LLC ,DEKK-TEC, Inc. ,DexTech Medical AB ,Diffusion Pharmaceuticals Inc. ,Dongkook Pharmaceutical Co., Ltd. ,DormaTarg, Inc. ,Eisai Co., Ltd. ,Eli Lilly and Company ,Emergent BioSolutions Inc. ,Enceladus Pharmaceuticals BV ,Endo Pharmaceuticals Inc. ,EndoCeutics, Inc. ,Endocyte, Inc. ,EntreChem, S.L. ,Errant Gene Therapeutics, LLC ,Esperance Pharmaceuticals, Inc. ,ESSA Pharma Inc ,Eureka Therapeutics, Inc. ,Evgen Pharma Plc ,Exonate Limited ,F. Hoffmann-La Roche Ltd. ,Ferring International Center S.A. ,Foresee Pharmaceuticals, LLC ,Fountain Biopharma Inc. ,Fujifilm Corporation ,G1 Therapeutics, Inc. ,Galectin Therapeutics, Inc. ,Genelux Corporation ,Genentech, Inc. ,Genmab A/S ,GenSpera, Inc. ,Gilead Sciences, Inc. ,Glactone Pharma AB ,GlaxoSmithKline Plc ,GlycoMimetics, Inc. ,GP Pharm, S.A. ,GTx, Inc. ,Hadasit Medical Research Services & Development Ltd ,Hybrigenics S.A. ,IC-MedTech, Inc. ,Ideaya Biosciences, Inc. ,IGF Oncology, LLC. ,Ignyta, Inc. ,Immune Pharmaceuticals Inc. ,Immuneed AB ,Immunocore Limited ,ImmunoFrontier, Inc. ,Immunomedics, Inc. ,Immupharma Plc ,Incanthera Ltd. ,Incuron, LLC ,Innate Immunotherapeutics Ltd ,Inovio Pharmaceuticals, Inc. ,Io Therapeutics, Inc. ,Ipsen S.A. ,Jiangsu Hengrui Medicine Co., Ltd. ,Johnson & Johnson ,Jyant Technologies, Inc. ,KaloBios Pharmaceuticals, Inc. ,Karyopharm Therapeutics, Inc. ,Kite Pharma, Inc. ,Komipharm International Co., Ltd. ,Kura Oncology, Inc. ,Kyowa Hakko Kirin Co., Ltd. ,Lidds AB ,Luye Pharma Group Ltd. ,MacroGenics, Inc. ,Mallinckrodt Plc ,MaxiVAX SA ,Meabco A/S ,Mebiopharm Co., Ltd. ,MediaPharma s.r.l. ,Medicenna Therapeutics, Inc. ,MediGene AG ,MedImmune, LLC ,Mediolanum farmaceutici S.p.A. ,Medivation, Inc. ,MEI Pharma, Inc. ,Merck & Co., Inc. ,Merck KGaA ,Millennium Pharmaceuticals, Inc. ,Minerva Biotechnologies Corporation ,Mirna Therapeutics, Inc. ,Mithra Pharmaceuticals S.A. ,MolMed S.p.A. ,Monopar Therapeutics LLC ,Morphotek, Inc. ,NewLink Genetics Corporation ,NormOxys, Inc. ,Novartis AG ,Novogen Limited ,Nymox Pharmaceutical Corporation ,Oasmia Pharmaceutical AB ,Omeros Corporation ,Omnitura Therapeutics Inc. ,OncBioMune Pharmaceuticals Inc. ,Oncodrone BV ,Oncogenex Pharmaceuticals, Inc. ,Oncolix, Inc. ,Oncolytics Biotech Inc. ,OncoMax ,OncoNOx ApS ,OncoTartis, Inc. ,Oncovir, Inc. ,OncoVista Innovative Therapies, Inc. ,ORCA Therapeutics B.V. ,Oribase Pharma ,Orion Oyj ,Orphagen Pharmaceuticals, Inc. ,Otsuka Holdings Co., Ltd. ,OXiGENE, Inc. ,Panacela Labs, Inc. ,PDS Biotechnology Corporation ,Peptron, Inc. ,Pfizer Inc. ,Pharmedartis GmbH ,Pharmicell Co., Ltd. ,Pharminox Limited ,Polaris Pharmaceuticals, Inc. ,Polyplus-Transfection SA ,Prima BioMed Ltd. ,Princeton University ,Progenics Pharmaceuticals, Inc. ,Provectus Biopharmaceuticals, Inc. ,Provenance Biopharmaceuticals Corp. ,PSites Pharma GmbH ,Qu Biologics Inc. ,Quest PharmaTech Inc. ,RedHill Biopharma Ltd. ,Rexahn Pharmaceuticals, Inc. ,Rigontec GmbH ,Sanofi ,Sareum Holdings Plc ,SEEK Group ,Serometrix, LLC ,Shenogen Pharma Group Ltd. ,Snowdon Inc. ,Sophiris Bio, Inc. ,Soricimed Biopharma Inc. ,Sorrento Therapeutics, Inc. ,Sotio a.s. ,Stemline Therapeutics, Inc. ,Sunesis Pharmaceuticals, Inc. ,Supratek Pharma Inc. ,Synta Pharmaceuticals Corp. ,TaiGen Biotechnology Co., Ltd. ,Taiho Pharmaceutical Co., Ltd. ,Taiwan Liposome Company, Ltd. ,Takeda Pharmaceutical Company Limited ,Takis S.r.l. ,Targovax AS ,Tesaro, Inc. ,Teva Pharmaceutical Industries Ltd. ,Theravectys SA ,Theryte Limited ,Tiltan Pharma Ltd. ,Tokai Pharmaceuticals, Inc. ,TRACON Pharmaceuticals, Inc. ,TREAT U, S.A. ,TVAX Biomedical, Inc. ,Tyme Technologies, Inc. ,TyrNovo Ltd. ,UbiVac, LLC ,Ultimovacs AS ,Vaccibody AS ,ValiRx Plc ,Vasgen Limited ,Vault Pharma Inc. ,Vaxeal Holding SA ,Vaxon Biotech ,Vicore Pharma AB ,Vicus Therapeutics, LLC ,Viralytics Ltd. ,ViraTherapeutics GmbH ,Wilex AG ,WntResearch AB ,Xencor, Inc. ,Yungjin Pharm. Co., Ltd. ,Zensun (Shanghai) Sci & Tech Co., Ltd.

Photo - http://photos.prnewswire.com/prnh/20160728/393830LOGO

The report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects.

Get discount on this research report at http://www.rnrmarketresearch.com/contacts/discount?rname=647173

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape of Prostate Cancer
• The report reviews pipeline therapeutics for Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Prostate Cancer therapeutics and enlists all their major and minor projects
• The report assesses Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Prostate Cancer

Complete research report of 1555 pages with TOC is available at http://www.rnrmarketresearch.com/prostate-cancer-pipeline-review-h1-2016-market-report.html

Media Contact: Ritesh Tiwari, RnR Market Research, + 1 888 391 5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnR Market Research